Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia. In April 2021, Neurocrine entered into a research collaboration with Sentia Medical Sciences, Inc., for the discovery of novel peptide CRF receptor antagonists, including NBIP-01435, for which Neurocrine has exclusive rights to develop and commercialize.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine presents new data analyses from KINECT-HD study
- Neurocrine presents new data on patient-reported improvements with INGREZZA
- Neurocrine names Lewis Choi as Chief Information Officer
- Neurocrine announces new data from Phase 4 KINECT-PRO study
- Neurocrine Announces Leadership Transition with New CMO